• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 12.09
  • VXN 15.15
  • VXO 12.04
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





YES
Refresh      
MNKD (MannKind Corporation)
Last Trade 1.53 Dividend/Share 0 PE Ratio -2.47
Date April 18-2019 Dividend Yield 0.000 Return on Assets -90.47
Change -0.01 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -0.61 Price/Sale 11.854
Ask null LatestEPS Date 2018-12-31 Price to Book 187.85
Volume null EPS ttm -0.620 Institutional % 45.7
Avg Volume 3.4M Shares Outstanding 187.77M Insider % 3.8
Open 1.53 Float 183.3M Short Ratio null
Prev Close 1.54 Return On Equity 44.62 5 Year Change % -0.952
High 1.57 Consensus EPS -0.08 2 Year Change % 0.654
Low 1.46 No. of Estimate 3.000 1 Year Change % -0.105
52 Week High 3.04 EPS Surprise $ null YTD Change % 0.302
52 Week Low 0.94 EPS Surprise Percent 0 6 Month Change % -0.182
52 Week Change -8.383 EBITDA 0M 3 Month Change % 0.093
50 Day MA 1.7752 Revenue 0M 1 Month Change % -0.305
200 Day MA Gross Profit 0M 5 Day Change % -0.084
Market Cap 287.29M Cash 0M 30 Day Change % -0.164
Beta 2.618966 Debt 0M Stock Exchange NASDAQ Global Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Its lead product candidate, AFREZZA, a rapid-acting insulin that has completed Phase III clinical trials for the treatment of diabetes in the United States, Europe, and Japan. The company is also preparing to initiate a Phase II study of MKC1106-MT in patients with advanced melanoma. Its products also include MKC253 (GLP-1), a Phase I clinical trials product for the treatment of type 2 diabetes; and MKC1106-PP, a Phase I clinical trials product for the treatment of diverse tumor types, metastatic diseases, and/or progressive, refractory disease. In addition, the company conducts preclinical studies of drug candidates, MKC204, which may have the potential to treat certain malignancies and inflammatory diseases; MKC180, an obesity compound; and MKC1106-NS, a cancer immunotherapy product. MannKind Corporation was founded in 1991 and is based in Valencia, California.